A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Maze Therapeutics, Inc. MAZE

Mixed (early) broader-coverage candidate · Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.

On FrontierLab's discovery record since 2026-09-14 (3 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-23), not the curated Frontier signal.

⚡ Surfaced on a price move — momentum is where to look, not a buy signal. The move that surfaced this name does not make it a good entry.

⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.

Key quality signals

Revenue growth (YoY)	700%
Gross margin	95.3%
Gross profits / assets	0.04
Rule of 40	-28.1
Net margin	-728.1%
Cash runway (months)	46.3
PEG	—
Price / sales	78.5

Quality checklist

~ Revenue growth — 700% (pass ≥ 20%)
✗ Capital efficiency
✓ Gross margin — 95.3% (pass ≥ 60%)
✓ Gross-margin trend — 21.3 (pass ≥ 2)
✓ Share dilution — 34.5%

Fundamentals — snapshot as of 2026-09-23

Stage	Early
Share issuance (YoY)	34.5% · heavy issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-2.74
Burn multiple	5.3
Gross-margin trend (pts)	21.3
Cash / assets	0.77
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-11

Momentum context — a snapshot from 2026-09-23, not current

Price at surface	$28.38 (as of 2026-09-23)
52-week range	$21.95 – $53.65
% off 52-wk high	-47.1%
RSI (14)	60
Relative volume	5.2×

Risk flags

Burning cash — operating margin is negative.Heavy dilution (~35%/yr) — top-decile share issuers have historically underperformed.Hyper-expansion — assets up ~75% in a year; aggressive expanders have historically lagged.Parabolic one-day spike (+27%) in the last month — extreme single-day moves tend to mean-revert.Volume 5.2× normal alongside the move — attention-crowded names tend to reverse over the following weeks.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-23 (end-of-day). How grades are computed →